Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05032859 · ClinicalTrials.gov registry record · Phase 3
Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (DMVT-505-3102)
A Phase 3 study of Atopic Dermatitis, sponsored by Organon and.
- Completed
- Registry status
- Phase 3
- Development phase
- 406
- Enrollment target
- 20
- Study locations
NCT05032859: Completed Phase 3 study of Atopic Dermatitis, sponsored by Organon and.
NCT05032859 is a Phase 3 study of Atopic Dermatitis that has completed, run by Organon and. The registered enrollment target is 406 participants, below the 607-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (33% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05032859, a Phase 3 study of Atopic Dermatitis, has completed, sponsored by Organon and.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 406 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a double-blind, randomized, vehicle controlled Phase 3 study to evaluate the efficacy and safety of topical tapinarof cream, 1% compared to vehicle control cream in pediatric and adult subjects with atopic dermatitis.
Primary Outcome
The vIGA-AD is a global assessment of the current state of the disease. It is a static 5-point scale used to grade overall disease severity (scalp excluded), as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. The vIGA-AD ranges from 0 to 4 and is calculated as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher vIGA-AD scores represent more severe disease. Statistics are based on 100
Conditions Studied
Interventions
- DRUG tapinarof cream, 1%
- DRUG vehicle cream
Study Locations (20)
California
- Dermavant Investigative Site - Cerritos
- Dermavant Investigative Site - Huntington Beach
- Dermavant Investigative Site - Lancaster
- Dermavant Investigative Site - Long Beach
- Dermavant Investigative Site - Los Angeles
- Dermavant Investigative Site - San Diego
- Dermavant Investigative Site - San Francisco
- Dermavant Investigative Site - Santa Ana
- Dermavant Investigative Site - Santa Monica
Florida
- Dermavant Investigative Site - Boca Raton
- Dermavant Investigative Site - Delray Beach
- Dermavant Investigative Site - Jacksonville
- Dermavant Investigative Site - Miami
- Dermavant Investigative Site - Miami
- Dermavant Investigative Site - Miami Lakes
- Dermavant Investigative Site - Tampa
Arizona
- Dermavant Investigative Site - Scottsdale
- Dermavant Investigative Site - Scottsdale
Alabama
- Dermavant Investigative Site - Birmingham
Arkansas
- Dermavant Investigative Site - Fort Smith
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 406 participants |
| Start Date | 2021-09-23 |
| Est. Completion | 2023-02-08 |
| Phase | Phase 3 |
What the finished NCT05032859 record still lists
NCT05032859 is an interventional study that assigns participants to a tested intervention. The registered 406 participants enrollment target is mid-sized for trials with a published cap, below the 607-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (33% lower).
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which tapinarof cream, 1% is the first listed.
NCT05032859 names 20 study sites across 5 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT05032859 about?
NCT05032859 is a clinical study titled "Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (DMVT-505-3102)". This is a double-blind, randomized, vehicle controlled Phase 3 study to evaluate the efficacy and safety of topical tapinarof cream, 1% compared to vehicle control cream in pediatric and adult subjects with atopic dermatitis.
What is the current status of trial NCT05032859?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 406 participants. The study started on 2021-09-23. Estimated completion is 2023-02-08.
What conditions does trial NCT05032859 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT05032859?
The interventions under investigation include: tapinarof cream, 1% (DRUG), vehicle cream (DRUG).
Who is sponsoring clinical trial NCT05032859?
This trial is sponsored by Organon and, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05032859 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05032859's enrollment target sits among peer trials
406 32nd of 150 higher than 119 of 150 other Atopic Dermatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
RECRUITING · Phase 3
-
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
RECRUITING · Phase 3
-
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
RECRUITING · Phase 3
-
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
RECRUITING · Phase 3
-
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06223360 · 406 participants · Phase 2
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
- NCT06411769 · 406 participants · NA
Evidence-based Intervention to Improve Walking Engagement in El Paso, Texas
- NCT06585787 · 406 participants · Phase 3
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
- NCT06735534 · 407 participants · NA
Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI